BAVARIAN NORDIC

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: -

Established: 1992-01-01

Employees: 759

Market Cap: $3.1B

Website: http://www.bavarian-nordic.com

Clinical Trials

RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults

Phase 2

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: MVA-BN-RSV
Other: Placebo

First Posted Date: 2016-08-19

Last Posted Date: 2020-09-22

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 420

Registration Number: NCT02873286

Locations: 🇺🇸
Rapid Medical Research, Cleveland, Ohio, United States
🇺🇸
Clinical Research Atlanta, Stockbridge, Georgia, United States
🇺🇸
United Medical Associates, Binghamton, New York, United States

and more 7 locations

RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.

Phase 1

Withdrawn

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: MVA-BN-RSV
Other: Placebo

First Posted Date: 2016-08-12

Last Posted Date: 2018-08-27

Lead Sponsor: Bavarian Nordic

Registration Number: NCT02864628

A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Biological: CV301
Biological: Pembrolizumab
Biological: Nivolumab

First Posted Date: 2016-07-21

Last Posted Date: 2020-02-27

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 24

Registration Number: NCT02840994

Locations: 🇺🇸
Metairie Oncologist, LLC, Metairie, Louisiana, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States

and more 4 locations

Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine

Phase 1

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: MVA BN RSV
Other: Placebo

First Posted Date: 2015-04-17

Last Posted Date: 2016-08-10

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 63

Registration Number: NCT02419391

Locations: 🇺🇸
Johnson County Clin-Trials (JCCT), Lenexa, Kansas, United States

Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers

Completed

Conditions: Typhoid Fever

Interventions: Biological: Vivotif

First Posted Date: 2015-03-18

Last Posted Date: 2023-07-07

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 855

Registration Number: NCT02391909

Locations: 🇺🇸
Passport Health, Baltimore, Maryland, United States

A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults

Phase 3

Completed

Conditions: Cholera

Interventions: Biological: PXVX0200
Biological: Placebo

First Posted Date: 2014-04-01

Last Posted Date: 2023-06-28

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 398

Registration Number: NCT02100631

Locations: 🇺🇸
Central Kentucky Research, Lexington, Kentucky, United States
🇺🇸
Center for Pharmaceutical Research, Kansas City, Missouri, United States
🇺🇸
St. Louis University, Saint Louis, Missouri, United States

and more 13 locations

A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults

Phase 3

Completed

Conditions: Cholera

Interventions: Biological: PXVX0200 Lot B
Biological: Placebo
Biological: PXVX0200 Lot A
Biological: PXVX0200 Lot C

First Posted Date: 2014-03-24

Last Posted Date: 2023-06-28

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 3146

Registration Number: NCT02094586

Locations: 🇺🇸
Miami Research Associates, Miami, Florida, United States
🇺🇸
Central Kentucky Research, Lexington, Kentucky, United States
🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia

and more 22 locations

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

Phase 2

Completed

Conditions: Smallpox

Interventions: Biological: IMVAMUNE®

First Posted Date: 2014-01-17

Last Posted Date: 2020-04-02

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 87

Registration Number: NCT02038881

Locations: 🇺🇸
Rowan Tree Medical, Wilton Manors, Florida, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Quest Clinical Research, San Francisco, California, United States

and more 9 locations

A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®

Phase 3

Completed

Conditions: 18-42 Year Old Healthy Vaccinia-naïve Subjects

Interventions: Biological: MVA BN®
Biological: ACAM2000®

First Posted Date: 2013-08-01

Last Posted Date: 2019-12-05

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 440

Registration Number: NCT01913353

Locations: 🇰🇷
Brian Allgood Army Community Hospital, Seoul, Korea, Republic of

Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera

Phase 3

Completed

Conditions: Cholera

Interventions: Biological: PXVX0200
Biological: placebo

First Posted Date: 2013-07-11

Last Posted Date: 2023-06-28

Lead Sponsor: Bavarian Nordic

Target Recruit Count: 197

Registration Number: NCT01895855

Locations: 🇺🇸
Cincinnati Children'S Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
University of Maryland Baltimore, Baltimore, Maryland, United States
🇺🇸
University of Vermont, Burlington, Vermont, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy